New antibody weapon targets Hard-to-Treat blood cancers
NCT ID NCT04606433
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 27 times
Summary
This early-stage study tests a new drug called GNC-038, a quad-specific antibody designed to attack cancer cells in multiple ways. It is for people with certain blood cancers (non-Hodgkin's lymphoma or acute lymphoblastic leukemia) that have come back or not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
-
Hematology Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300000, China
-
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China
-
Peking University Third Hospital
Beijing, Beijing Municipality, China
-
Shanghai Tongji Hospital
Shanghai, Shanghai Municipality, China
-
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
-
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
-
Xiangya Hospital Central South University
Changsha, Hunan, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.